Payment overview · 2025
General Payments
$1,206.59
64 reported records · 15 companies
Healthcare provider profile · identity verified
Wesley Clark Ray, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1063403434
Verified facts
What the public records show
CMS Open Payments records show Wesley Clark Ray, M.D. received $1,206.59 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $369.50 | 30.6% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.35 | 14.5% | 12 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $141.77 | 11.8% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.63 | 8.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.65 | 7.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.13 | 7.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.51 | 5.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.13 | 4.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.33 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.38 | 1.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.46 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.23 | 1.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.04 | 1.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,206.59 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $276.93 | 10 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $141.77 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.36 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.63 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.63 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.81 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.57 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.65 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $84.13 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.51 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.13 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.38 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 174 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 94 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
174 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 611 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 605 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 423 | 116 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 377 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 107 |
| Losartan Potassium | Losartan Potassium | 276 | 70 |
| Gabapentin | Gabapentin | 275 | 46 |
| Methylprednisolone | Methylprednisolone | 270 | 172 |
| Omeprazole | Omeprazole | 238 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 208 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 195 | 47 |
| Clonazepam | Clonazepam | 193 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 48 |
| Montelukast Sodium | Montelukast Sodium | 185 | 42 |
| Ozempic | Semaglutide | 174 | 24 |
| Furosemide | Furosemide | 173 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 51 |
| Azithromycin | Azithromycin | 166 | 97 |
| Meloxicam | Meloxicam | 162 | 42 |
| Diazepam | Diazepam | 154 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 47 |
| Lisinopril | Lisinopril | 147 | 34 |
| Famotidine | Famotidine | 145 | 37 |
| Ondansetron Odt | Ondansetron | 145 | 46 |
| Pregabalin | Pregabalin | 142 | 29 |
| Glimepiride | Glimepiride | 141 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 139 | 72 |
| Metformin Hcl | Metformin Hcl | 134 | 38 |
| Potassium Chloride | Potassium Chloride | 131 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 127 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 114 | 34 |
| Fluconazole | Fluconazole | 113 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 22 |
| Estradiol | Estradiol | 112 | 24 |
| Trazodone Hcl | Trazodone Hcl | 112 | 23 |
| Tramadol Hcl | Tramadol Hcl | 106 | 24 |
| Cephalexin | Cephalexin | 105 | 62 |
| Lorazepam | Lorazepam | 105 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 27 |
| Donepezil Hcl | Donepezil Hcl | 104 | 20 |
| Valsartan | Valsartan | 103 | 27 |
| Simvastatin | Simvastatin | 99 | 27 |
| Sertraline Hcl | Sertraline Hcl | 97 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 33 |
| Synthroid | Levothyroxine Sodium | 94 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 22 |
| Prednisone | Prednisone | 88 | 21 |
| Eliquis | Apixaban | 83 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 83 | 25 |
| Celecoxib | Celecoxib | 81 | 22 |
| Irbesartan | Irbesartan | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 21 |
| Promethazine Hcl | Promethazine Hcl | 78 | 13 |
| Xarelto | Rivaroxaban | 77 | 16 |
| Spironolactone | Spironolactone | 76 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | suppressed |
| Bupropion Xl | Bupropion Hcl | 74 | 21 |
| Allopurinol | Allopurinol | 73 | 17 |
| Aripiprazole | Aripiprazole | 73 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | suppressed |
| Temazepam | Temazepam | 73 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 72 | 15 |
| Ibuprofen | Ibuprofen | 71 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 40 |
| Lamotrigine | Lamotrigine | 67 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Farxiga | Dapagliflozin Propanediol | 66 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 62 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 14 |
| Baclofen | Baclofen | 57 | 18 |
| Eszopiclone | Eszopiclone | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 51 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 31 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 46 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 44 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 12 |
| Atenolol | Atenolol | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 21 |
| Linzess | Linaclotide | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Clonidine Hcl | Clonidine Hcl | 32 | 15 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Naproxen | Naproxen | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 18 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Torsemide | Torsemide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Etodolac Er | Etodolac | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,206.59 · 64 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Quviviq, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error